Tesla has successfully completed its first unsupervised Full Self-Driving delivery, navigating a vehicle from the factory directly to a customer in Austin, Texas. This pivotal milestone could significantly enhance operational...
Discover a promising opportunity with Wearable Devices Ltd. (WLDS) as it navigates the burgeoning neural interface market, backed by strategic partnerships with Qualcomm and TCL-RayNeo. Positioned for substantial growth, WLDS’s...
Iris Energy's ambitious Sweetwater project in Texas presents a staggering $70 billion funding challenge against a mere $200 million cash reserve. As they pivot towards AI and HPC infrastructure alongside...
Tonix Pharmaceuticals offers a unique investment opportunity with its leading candidate, TNX-102 SL, poised to disrupt the $2.1 billion fibromyalgia market. Sporting a robust cash position and no debt, the...
ImmunityBio emerges as a standout in the immuno-oncology sector with a "Buy" recommendation and a target price of $8.00. The company capitalises on robust revenue growth, recent FDA approvals, and...
Iveda Solutions Inc. (IVDA) offers an intriguing investment opportunity in the AI-driven security sector, with a 40.6% upside potential reflected in the 12-month price target. Despite accelerating revenue growth from...
In the world of investing, operational efficiency might just be the unsung hero. While seductive growth narratives often take centre stage, the real action lies in how well a company...
OpenAI's surprising shift from NVIDIA's GPUs to Google's TPUs could reshape AI hardware dynamics. This pivot hints at cost efficiencies and supply chain resilience, challenging NVIDIA's dominance. As Google strengthens...
In the dynamic world of investments, our latest analysis favours a quartet of under-the-radar contenders. We dive into why AMD may outpace NVIDIA, NBIS might edge out CRWV, SOFI could...
AbCellera Biologics Inc. (ABCL) emerges as a notable player in the AI-driven drug discovery realm, targeting a 12-month price of $17.00, a potential leap from the current valuation. This optimism...
